Bone disease in eliglustat treated Gaucher disease type 1 patients: A real-world experience in a tertiary referral hospital

被引：0
|
作者：
Valls-Villalba, Angel [1 ]
Camprodon-Gomez, Maria [2 ]
Moreno-Martinez, Daniel [3 ]
Hernandez-Vara, Jorge [4 ]
Arranz-Amo, Jose Antonio [5 ]
Carnicer-Caceres, Clara [5 ]
机构：
[1] Vall Hebron Univ Hosp, Internal Med, Barcelona, Spain
[2] Vall DHebron Univ Hosp, Unit Rare Dis & Metab Hereditary Disorders, Barcelona, Spain
[3] Vall Hebron Univ Hosp, Dept Radiol, Barcelona, Spain
[4] Vall Hebron Univ Hosp, Dept Neurol, Unit Movement Disorders, Barcelona, Spain
[5] Vall Hebron Univ Hosp, Inborn Error Metab Lab, Barcelona, Spain
来源：
MOLECULAR GENETICS AND METABOLISM | 2023年 / 138卷 / 02期
关键词：
D O I：
10.1016/j.ymgme.2022.107340
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
357
引用
收藏
页码：129 / 129
页数：1
相关论文
共 50 条
  • [1] Patient reported outcomes of patients with Gaucher disease type 1 treated with eliglustat in real-world settings: The ELIPRO study
    Camou, Fabrice
    Lagadec, Audrey
    Coutinho, Angela
    Berger, Marc G.
    Cador-Rousseau, Berengere
    Gaches, Francis
    Belmatoug, Nadia
    [J]. MOLECULAR GENETICS AND METABOLISM, 2023, 140 (03)
  • [2] A Real-World Investigation of MRI Changes in Bone in Patients with Type 1 Gaucher Disease Treated with Velaglucerase Alfa: The EIROS Study
    Bengherbia, Monia
    Berger, Marc
    Hivert, Benedicte
    Rigaudier, Florian
    Bracoud, Luc
    Vaeterlein, Ole
    Yousfi, Karima
    Maric, Michele
    Malcles, Marie
    Belmatoug, Nadia
    [J]. JOURNAL OF CLINICAL MEDICINE, 2024, 13 (10)
  • [3] Eliglustat: A Review in Gaucher Disease Type 1
    Scott, Lesley J.
    [J]. DRUGS, 2015, 75 (14) : 1669 - 1678
  • [4] ELISAFE: Baseline characteristics from an observational study to evaluate real-world safety of eliglustat in patients with Gaucher disease
    Batsu, Isabela
    Accomando, Beverly
    Gaemers, Sebastiaan J. M.
    Sekulic, Davorka
    [J]. MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S21 - S22
  • [5] Clinical response to eliglustat in treatment-naive patients with Gaucher disease type 1: Post-hoc comparison to imiglucerase in a real-world setting
    Peterschmitt, M. Judith
    Taylor, John S.
    Angell, Jennifer
    Ibrahim, Jennifer
    [J]. MOLECULAR GENETICS AND METABOLISM, 2015, 114 (02) : S93 - S93
  • [6] Real-Life Experience with Oral Eliglustat in Patients with Gaucher Disease Previously Treated with Enzyme Replacement Therapy
    Istaiti, Majdolen
    Becker-Cohen, Michal
    Dinur, Tama
    Revel-Vilk, Shoshana
    Zimran, Ari
    [J]. JOURNAL OF CLINICAL MEDICINE, 2022, 11 (21)
  • [7] Gaucher disease: French cohort of the 58 patients treated by eliglustat
    Camou, F.
    Bengherbia, M.
    Verstuyft, C.
    Stirnemann, J.
    Belmatoug, N.
    Berger, M. G.
    [J]. FUNDAMENTAL & CLINICAL PHARMACOLOGY, 2018, 32 : 25 - 25
  • [8] Bone involvement outcomes in Spanish patients with Gaucher disease type 1 treated with eliglustat: Sub-study International Collaborative Gaucher Group (ICGG)
    Camprodon-Gomez, Maria
    Valls-Villalba, Angel
    Riera, Mireia Del Toro
    [J]. MOLECULAR GENETICS AND METABOLISM, 2024, 141 (02)
  • [9] Population pharmacokinetics of eliglustat in patients with Gaucher Disease Type 1 (GD1)
    Lu, Qiang
    Gao, Yue
    Li, Jing
    Kanamaluru, Vanaja
    [J]. JOURNAL OF PHARMACOKINETICS AND PHARMACODYNAMICS, 2018, 45 : S127 - S128
  • [10] Eliglustat in patients with Gaucher disease previously treated with enzyme replacement therapy: Real-life experience from Israel
    Istaiti, Majdolen
    Ruhrman-Shahar, Noa
    Cohen, Ian J.
    Hershkovitz, Tova
    Becker-Cohen, Michal
    Dinur, Tama
    Revel-Vilk, Shoshana
    Zimran, Ari
    [J]. MOLECULAR GENETICS AND METABOLISM, 2022, 135 (02) : S61 - S61
12345